LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Meningoencephalitis due to Mycobacterium lentiflavum in an immunocompromised patient: Case report.

    Martinez-Poles, Javier / Saldaña-Díaz, Ana Isabel / Esteban, Jaime / Lara-Almunia, Mónica / Vizarreta Figueroa, Anthony Tito / Martín-Gil, Leticia / Cebrián-Escudero, José / Fernández-Ferro, José

    European journal of neurology

    2022  Band 30, Heft 4, Seite(n) 1152–1154

    Abstract: The first case of meningoencephalitis due to Mycobacterium lentiflavum in an immunocompromised patient is reported. Clinical and radiological characteristics are described, as well as the treatment and prognosis of the patient. ...

    Abstract The first case of meningoencephalitis due to Mycobacterium lentiflavum in an immunocompromised patient is reported. Clinical and radiological characteristics are described, as well as the treatment and prognosis of the patient.
    Mesh-Begriff(e) Humans ; Nontuberculous Mycobacteria ; Mycobacterium ; Meningoencephalitis
    Sprache Englisch
    Erscheinungsdatum 2022-12-26
    Erscheinungsland England
    Dokumenttyp Case Reports
    ZDB-ID 1280785-0
    ISSN 1468-1331 ; 1351-5101 ; 1471-0552
    ISSN (online) 1468-1331
    ISSN 1351-5101 ; 1471-0552
    DOI 10.1111/ene.15659
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Pharmacokinetic variability of eslicarbazepine in real clinical practice.

    de Toledo, Maria / Valladares-Salado, Laura / Cebrian-Escudero, Jose / Diaz-Perez, Carolina / de la Fuente, Elisa / Ferreiros, Raquel / Sanz-Sanz, Elena / Vega-Piris, Lorena / Lagares, Alfonso / Ovejero-Benito, Maria C / Sobrado, Monica

    Epilepsy & behavior : E&B

    2021  Band 124, Seite(n) 108284

    Abstract: Introduction: Eslicarbazepine acetate (ESL) is a sodium channel blocker indicated for partial-onset seizures with or without secondary generalization, at a single daily dose. There are very few publications on the levels of ESL metabolites in real ... ...

    Abstract Introduction: Eslicarbazepine acetate (ESL) is a sodium channel blocker indicated for partial-onset seizures with or without secondary generalization, at a single daily dose. There are very few publications on the levels of ESL metabolites in real clinical practice.
    Objective: To describe the serum levels of licarbazepine (main metabolite of ESL) in patients with refractory epilepsy in real clinical practice. To evaluate the influence of age, sex, and polytherapy on levels and adverse effects.
    Methods: This study involved a retrospective analysis of patients diagnosed with epilepsy treated with ESL for whom plasma levels of licarbazepine were available, measured by spectrophotometry.
    Results: Sixty-four patients were included. One patient had licarbazepine levels of 0 (admitted not taking the drug) was not analyzed. Mean licarbazepine levels of 7.66 µg/mL (400 mg/day dose), 16.56 µg/mL (800-mg dose), and 20.80 µg/mL (1200 mg) were significantly different. There was a significant correlation between daily dose and serum levels (p < 0.05) and between the concentration/dose ratio and lower to higher doses (p < 0.05). Pharmacokinetic variability (coefficient of variation for the concentration/dose ratio) was 33.2%. We found a decrease in the concentration/dose ratio in the 1200 mg/day dose, compared to lower doses. We did not find differences by sex or intake of other antiepileptic inducers or metabolic inhibitors. Fifteen patients (23.8%) had mild nonsymptomatic hyponatremia.
    Conclusion: These results suggest that it is not necessary to routinely determine licarbazepine levels. In specific cases, licarbazepine levels can be useful to assess adherence to treatment and for personalized dose adjustment.
    Sprache Englisch
    Erscheinungsdatum 2021-09-11
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2010587-3
    ISSN 1525-5069 ; 1525-5050
    ISSN (online) 1525-5069
    ISSN 1525-5050
    DOI 10.1016/j.yebeh.2021.108284
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang